Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.45 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626417 | 0.93 | CYP19A1 (0.55) | CYP19A1CYP26A1CYP3A4CYP2C8CYP2D6 | |
| Water SCHEMBL9727730 | 0.87 | CYP19A1 (0.61) | CYP19A1CYP26A1CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL669025 | 0.84 | CYP19A1 (0.58) | CYP19A1CYP26A1CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL9190606 | 0.83 | CYP26A1 (0.53) | CYP19A1CYP26A1CYP3A4FNTAFNTB | |
| SCHEMBL668660 | 0.80 | CYP19A1 (0.59) | CYP19A1CYP26A1FNTAFNTBCNR1 | |
| SCHEMBL9198108 | 0.79 | CYP19A1 (0.60) | CYP19A1CYP26A1CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL12336821 | 0.78 | CYP19A1 (0.52) | CYP19A1CYP26A1CYP3A4CYP2C8CYP2D6 | |
| Irtemazole SCHEMBL636285 | 0.77 | CYP26A1 (0.57) | CYP19A1CYP26A1CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL12337076 | 0.77 | CYP19A1 (0.53) | CYP19A1CYP26A1CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL9196231 | 0.76 | CYP19A1 (0.57) | CYP19A1CYP26A1CYP3A4CYP2C8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709011-B1 | 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2 QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| US-8524714-B2 | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-03 | — | — | US | disclosed |
| US-20110230492-A1 | 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE | 2011-09-22 | — | — | US | disclosed |
| US-7928104-B2 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928104-B2 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20080249099-A1 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249099-A1 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249099-A1 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | PARP1, PARP2, PARP3 | CYP19A1 470/4885CYP26A1 2379/4885CYP3A4 165/4885 |
| US-20110230492-A1 | 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | CYP19A1 933/4885CYP26A1 2881/4885CYP3A4 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.